Expand all sections

Delafloxacin

Quofenix

Extended indication Community acquired pneumonia
Therapeutic value No judgement yet
Registration phase Clinical trials

Product

Active substance Delafloxacin
Domain Infectious diseases
Reason of inclusion Indication extension
Main indication Bacterial infections
Extended indication Community acquired pneumonia
Proprietary name Quofenix
Manufacturer Menarini
Mechanism of action Antibiotic
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Additional remarks Ook beschikbaar als tablet. DNA gyrase inhibitor; DNA topoisomerase IV inhibitor; Protein 50S ribosomal subunit inhibitor.

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date 2019
Expected Registration 2020
Orphan drug No
Registration phase Clinical trials
Additional remarks Indiening voor deze indicatie bij de FDA verwacht in H1 2019.

Therapeutic value

Current treatment options Afhankelijk van de diagnose: amoxicilline, doxycycline, azitromycine, claritromycine, cotrimoxazol, levofloxacine, moxifloxacine.
Therapeutic value No judgement yet
Substantiation Geen meerwaarde tov levofloxacin en moxifloxacin.
Frequency of administration 2 times a day
Dosage per administration 300 - 450 mg
References Farmcotherapeutisch Kompas; NCT02679573
Additional remarks 300 mg IV, Q12H for at least 6 doses with potential to switch to 450 mg oral tablet, Q12H for up to 20 doses total

Expected patient volume per year

References Aleva en Boersma. Ned Tijdschr Geneeskd. 2005;149:2501-7; Verheij en Boudry, Ge-Bu, Nr 7, 2006 (40), Pagina 73-79
Additional remarks De incidentie van CAP in de huisartsenpraktijk is 5-8 per 1.000 patiënten per jaar (in totaal 85.000-136.000). Ongeveer één op de tien patiënten wordt in een ziekenhuis opgenomen (8.500-13.600). Het totaal aantal patiënten dat in aanmerking zal komen voor deze behandeling is verwaarloosbaar in Nederland bij CAP.

Expected cost per patient per year

References GoodRx.com
Additional remarks 20 tabletten van Baxdela 450mg betreft $1,350.00.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes

Other information

There is currently no futher information available.